Literature DB >> 7769728

Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes.

M Simm1, M Shahabuddin, W Chao, J S Allan, D J Volsky.   

Abstract

Productive, spreading infection of peripheral blood lymphocytes (PBL) with human immunodeficiency virus type 1 (HIV-1) requires the viral protein Vif. To study the requirement for vif in this system, we infected PBL with a phenotypically complemented HIV-1 clone mutated in vif. Progeny virus was produced which was noninfectious in PBL but replicated in SupT1 cells. Analysis of metabolically labeled proteins of sedimentable extracellular particles made in PBL by radioimmunoprecipitation with either serum from a patient with AIDS or a monoclonal antibody reactive with HIV-1 Gag proteins revealed that vif-negative but not wild-type particles carry higher levels of p55, p41, and p38 Gag-specific proteins compared with those of p24. Similar results were obtained with sucrose-purified virions. Our data indicate that vif plays a role in Gag protein processing or in incorporation of processed Gag products into mature virions. The presence of unprocessed precursor Gag polyprotein (Pr55gag) and other Gag processing intermediates in PBL-derived vif-negative extracellular particles may contribute to the reduced infectivity of this virus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7769728      PMCID: PMC189210          DOI: 10.1128/JVI.69.7.4582-4586.1995

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

2.  The HIV 'A' (sor) gene product is essential for virus infectivity.

Authors:  K Strebel; D Daugherty; K Clouse; D Cohen; T Folks; M A Martin
Journal:  Nature       Date:  1987 Aug 20-26       Impact factor: 49.962

3.  Characterization of ribosomal frameshifting in HIV-1 gag-pol expression.

Authors:  T Jacks; M D Power; F R Masiarz; P A Luciw; P J Barr; H E Varmus
Journal:  Nature       Date:  1988-01-21       Impact factor: 49.962

4.  The gag gene products of human immunodeficiency virus type 1: alignment within the gag open reading frame, identification of posttranslational modifications, and evidence for alternative gag precursors.

Authors:  R J Mervis; N Ahmad; E P Lillehoj; M G Raum; F H Salazar; H W Chan; S Venkatesan
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

5.  Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector.

Authors:  V Karacostas; K Nagashima; M A Gonda; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

6.  Rational design of peptide-based HIV proteinase inhibitors.

Authors:  N A Roberts; J A Martin; D Kinchington; A V Broadhurst; J C Craig; I B Duncan; S A Galpin; B K Handa; J Kay; A Kröhn
Journal:  Science       Date:  1990-04-20       Impact factor: 47.728

7.  Interaction of a noncytopathic human immunodeficiency virus type 1 (HIV-1) with target cells: efficient virus entry followed by delayed expression of its RNA and protein.

Authors:  X Y Ma; K Sakai; F Sinangil; E Golub; D J Volsky
Journal:  Virology       Date:  1990-05       Impact factor: 3.616

8.  Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines.

Authors:  S D Smith; M Shatsky; P S Cohen; R Warnke; M P Link; B E Glader
Journal:  Cancer Res       Date:  1984-12       Impact factor: 12.701

9.  The sor gene of HIV-1 is required for efficient virus transmission in vitro.

Authors:  A G Fisher; B Ensoli; L Ivanoff; M Chamberlain; S Petteway; L Ratner; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1987-08-21       Impact factor: 47.728

10.  A human T-cell line resistant to cytopathic effects of the human immunodeficiency virus (HIV).

Authors:  D Casareale; M Stevenson; K Sakai; D J Volsky
Journal:  Virology       Date:  1987-01       Impact factor: 3.616

View more
  67 in total

1.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 2.  HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors.

Authors:  Silke Wissing; Nicole L K Galloway; Warner C Greene
Journal:  Mol Aspects Med       Date:  2010-06-09

3.  Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag.

Authors:  P Sova; D J Volsky; L Wang; W Chao
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Probing the structural states of human immunodeficiency virus type 1 pr55gag by using monoclonal antibodies.

Authors:  Jason J Leblanc; Omar Perez; Thomas J Hope
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

5.  Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain.

Authors:  Jason T Newman; Timothy J Sturgeon; Phalguni Gupta; Ronald C Montelaro
Journal:  Virology       Date:  2007-06-19       Impact factor: 3.616

6.  Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet.

Authors:  Mario Perkovic; Stanislaw Schmidt; Daniela Marino; Rebecca A Russell; Benjamin Stauch; Henning Hofmann; Ferdinand Kopietz; Björn-Philipp Kloke; Jörg Zielonka; Heike Ströver; Johannes Hermle; Dirk Lindemann; Vinay K Pathak; Gisbert Schneider; Martin Löchelt; Klaus Cichutek; Carsten Münk
Journal:  J Biol Chem       Date:  2008-12-12       Impact factor: 5.157

7.  Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells.

Authors:  Alberto Bosque; Vicente Planelles
Journal:  Blood       Date:  2008-10-10       Impact factor: 22.113

8.  Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif.

Authors:  M J Potash; G Bentsman; T Muir; C Krachmarov; P Sova; D J Volsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

9.  Determinants for the rhesus monkey TRIM5alpha-mediated block of the late phase of HIV-1 replication.

Authors:  Ryuta Sakuma; Seiga Ohmine; Yasuhiro Ikeda
Journal:  J Biol Chem       Date:  2009-12-01       Impact factor: 5.157

10.  The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity.

Authors:  Sandra Kao; Mohammad A Khan; Eri Miyagi; Ron Plishka; Alicia Buckler-White; Klaus Strebel
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.